Archives — May 2014 back to current month (11)

ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn (05/28/2014)

Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1. Participants have submitted abstracts for promising therapies in advance of the conference, profiling new compounds that could lead to better outcomes for patients and bolster the health of investment portfolios. In this interview with The Life Sciences Report, LifeTech Capital's Stephen Dunn walks us through some of the highlights.

more>

Turn Solid Gold into Biotech Gold with James West (05/28/2014)

The globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space. In this interview with The Life Sciences Report, James West points to low-hanging biofruit ripe for the picking.

more>

Harnessing the Power of Nature's Perfect Cells: Robert J. Hariri (05/22/2014)

Neurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report. Hariri also discusses the special nature and advantages of placenta-derived stem cells, and an elegant solution to the scourge of muscle wasting in late-stage disease and advancing age that could apply to treatment of cardiovascular disease in the future.

more>

The Naysayers Are Wrong: Rohit Vanjani on How You Can Make Money with Generics and Diagnostics (05/22/2014)

The concept that generic and specialty pharmaceutical drugs cannot command pricing power and growth is a misunderstanding, according to Director and Senior Analyst Rohit Vanjani of Oppenheimer and Co. Diagnostics also offer upside to investors: In fact, some recent returns disprove misconceptions in a spectacular fashion. The secret to making excellent margins in generics is to find markets where a vacuum has been created and product safety can be assured. The trick with diagnostics is to offer new tests that save steps, increase accuracy and reduce the burden on payers. In this interview with The Life Sciences Report, Vanjani discusses three names that fit the bill for investors seeking powerful growth in not-so-obvious sectors.

more>

New Wave of M&A: Divestitures, Swaps and Inversions (05/22/2014)

"This latest quarter, which kicks off a third year of negative growth, seems to have been the tipping point for pharma companies to finally emerge from a long M&A hibernation."

more>

New Wave of M&A: Divestitures, Swaps and Inversions (05/22/2014)

"This latest quarter, which kicks off a third year of negative growth, seems to have been the tipping point for pharma companies to finally emerge from a long M&A hibernation."

more>

Think Like a Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives on Six Exciting Biotechs (05/15/2014)

New perspectives on well-followed biotech stocks are greatly appreciated. That's what we get here from Managing Director and Senior Biotechnology Analyst Christopher S. James M.D. of Brinson Patrick Securities. Something else that's treasured is discovering a brand-new biotech stock that no other analyst is covering. In this interview with The Life Sciences Report, James ushers readers to the head of the line to look at a new and exciting name with an extraordinary technology and phenomenal prospects for growth.

more>

J.P.Morgan's Geoff Meacham Plucks Biotechs with Upside from a Down Market (05/15/2014)

A downtrending market is troublesome for investors, but does present interesting opportunities through creation of lower valuations. Finding the right names in the wobbly life sciences environment requires a sharp eye and depth of experience. In this interview with The Life Sciences Report, J.P.Morgan Senior Biotechnology Analyst and Managing Director Geoff Meacham, a veteran analyst and cell biologist, brings eight important names to investors' attention and explains why they are still growth stories.

more>

Live Longer, Get Richer with Patrick Cox (05/08/2014)

It's what every biotech investor dreams of: transformational advances in healthcare technologies that allow us to live for centuries and accumulate wealth exponentially. Patrick Cox, editor of the Transformational Technology Alert, is doing his part to make the dream reality. In this interview, Cox tells The Life Sciences Report about two companies with proprietary intellectual property in DNA-based therapeutics and regenerative medicine that could change the world.

more>

7 Bits of News that Will Reshape Your Investment Outlook (05/07/2014)

"If you've ever wondered why developing a drug has to be so expensive, imagine what is going on in labs around the world, where scientists have been trying to figure out how to make a diet pill that turns off FTO, the so-called fat gene discovered seven years ago."

more>

X-Ray Vision or Due Diligence? How SeeThruEquity Analysts Find Hidden Small-Cap Biotech Plays (05/01/2014)

SeeThruEquity stays an arm's length away from the small biotech firms it analyzes for investors, but gets intimate enough to discover firms that hold promise. In this interview with The Life Sciences Report, senior analyst Brandon Primack and the firm's CEO, Ajay Tandon, explain why they find this handful of small biotechs intriguing.

more>

More Archives

2017Sep Aug Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe